TY - JOUR
TI - Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study
AU - Wang, L.
AU - Heckman, M.G.
AU - Aasly, J.O.
AU - Annesi, G.
AU - Bozi, M.
AU - Chung, S.J.
AU - Clarke, C.
AU - Crosiers, D.
AU - Eckstein, G.
AU - Garraux, G.
AU - Hadjigeorgiou, G.M.
AU - Hattori, N.
AU - Jeon, B.
AU - Kim, Y.J.
AU - Kubo, M.
AU - Lesage, S.
AU - Lin, J.J.
AU - Lynch, T.
AU - Lichtner, P.
AU - Mellick, G.D.
AU - Mok, V.
AU - Morrison, K.E.
AU - Quattrone, A.
AU - Satake, W.
AU - Silburn, P.A.
AU - Stefanis, L.
AU - Stockton, J.D.
AU - Tan, E.K.
AU - Toda, T.
AU - Brice, A.
AU - Van Broeckhoven, C.
AU - Uitti, R.J.
AU - Wirdefeldt, K.
AU - Wszolek, Z.
AU - Xiromerisiou, G.
AU - Maraganore, D.M.
AU - Gasser, T.
AU - Krüger, R.
AU - Farrer, M.J.
AU - Ross, O.A.
AU - Sharma, M.
JO - Neurobiology of Aging
PY - 2017
VL - 49
TODO - null
SP - 217.e1-217.e4
PB - ELSEVIER SCIENCE INC 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN - 0197-4580, 1558-1497
TODO - 10.1016/j.neurobiolaging.2016.09.022
TODO - leucine rich repeat kinase 2;  leucine rich repeat kinase 2;  LRRK2 protein, human, Article;  controlled study;  gene;  gene frequency;  gene interaction;  gene locus;  genetic risk;  genetic variability;  genotype;  human;  LRRK2 gene;  lysosome;  major clinical study;  PARK16 gene;  Parkinson disease;  priority journal;  single nucleotide polymorphism;  epistasis;  gene locus;  genetic association study;  genetic predisposition;  genetic variation;  genetics;  multicenter study (topic);  Parkinson disease;  risk, Epistasis, Genetic;  Genetic Association Studies;  Genetic Loci;  Genetic Predisposition to Disease;  Genetic Variation;  Humans;  Leucine-Rich Repeat Serine-Threonine Protein Kinase-2;  Multicenter Studies as Topic;  Parkinson Disease;  Risk
TODO - A recent study MacLeod et al. has shown that an interaction between variants at the LRRK2 and PARK16 loci influences risk of development of Parkinson's disease (PD). Our study examines the proposed interaction between LRRK2 and PARK16 variants in modifying PD risk using a large multicenter series of PD patients (7715) and controls (8261) from sites participating in the Genetic Epidemiology of Parkinson's Disease Consortium. Our data does not support a strong direct interaction between LRRK2 and PARK16 variants; however, given the role of retromer and lysosomal pathways in PD, further studies are warranted. © 2016 Elsevier Inc.
ER -